Myovant's Relugolix May Be Competitive With AbbVie Drug In Uterine Fibroids

 
• By Joseph Haas
  
uterine-fibroids
AbbVie, Myovant and ObsEva are competing to bring a GnRH antagonist to market for UF
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business